These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 1312584)

  • 1. High-dose carboplatin and etoposide with autologous bone marrow transplantation in refractory germ cell cancer: an Eastern Cooperative Oncology Group protocol.
    Nichols CR; Andersen J; Lazarus HM; Fisher H; Greer J; Stadtmauer EA; Loehrer PJ; Trump DL
    J Clin Oncol; 1992 Apr; 10(4):558-63. PubMed ID: 1312584
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dose-intensive chemotherapy in refractory germ cell cancer--a phase I/II trial of high-dose carboplatin and etoposide with autologous bone marrow transplantation.
    Nichols CR; Tricot G; Williams SD; van Besien K; Loehrer PJ; Roth BJ; Akard L; Hoffman R; Goulet R; Wolff SN
    J Clin Oncol; 1989 Jul; 7(7):932-9. PubMed ID: 2544687
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High-dose treatment with carboplatin, etoposide, and ifosfamide followed by autologous stem-cell transplantation in relapsed or refractory germ cell cancer: a phase I/II study. The German Testicular Cancer Cooperative Study Group.
    Siegert W; Beyer J; Strohscheer I; Baurmann H; Oettle H; Zingsem J; Zimmermann R; Bokemeyer C; Schmoll HJ; Huhn D
    J Clin Oncol; 1994 Jun; 12(6):1223-31. PubMed ID: 7911158
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I trial with pharmacokinetic analyses of high-dose carboplatin, etoposide, and cyclophosphamide with autologous bone marrow transplantation in patients with refractory germ cell tumors.
    Motzer RJ; Gulati SC; Tong WP; Menendez-Botet C; Lyn P; Mazumdar M; Vlamis V; Lin S; Bosl GJ
    Cancer Res; 1993 Aug; 53(16):3730-5. PubMed ID: 8393380
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High dose chemotherapy with ifosfamide, carboplatin, and etoposide combined with autologous bone marrow transplantation for the treatment of poor-prognosis germ cell tumors and metastatic trophoblastic disease in adults.
    Lotz JP; André T; Donsimoni R; Firmin C; Bouleuc C; Bonnak H; Merad Z; Esteso A; Gerota J; Izrael V
    Cancer; 1995 Feb; 75(3):874-85. PubMed ID: 7828139
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of germ cell cancer with two cycles of high-dose ifosfamide, carboplatin, and etoposide with autologous stem-cell support.
    Margolin K; Doroshow JH; Ahn C; Hamasaki V; Leong L; Morgan R; Raschko J; Shibata S; Somlo G; Tetef M
    J Clin Oncol; 1996 Oct; 14(10):2631-7. PubMed ID: 8874321
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dose escalation study of high-dose carboplatin and etoposide with autologous bone marrow support in patients with recurrent and refractory germ cell tumors.
    Broun ER; Nichols CR; Mandanas R; Salzman D; Turns M; Hromas R; Cornetta K; Einhorn LH
    Bone Marrow Transplant; 1995 Sep; 16(3):353-8. PubMed ID: 8535306
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High-dose chemotherapy with carboplatin, etoposide and ifosfamide followed by autologous stem cell rescue in patients with relapsed or refractory malignant lymphomas: a phase I/II study.
    Kleiner S; Kirsch A; Schwaner I; Kingreen D; Schwella N; Huhn D; Siegert W
    Bone Marrow Transplant; 1997 Dec; 20(11):953-9. PubMed ID: 9422474
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II trial of high-dose carboplatin and etoposide with autologous bone marrow transplantation in first-line therapy for patients with poor-risk germ cell tumors.
    Motzer RJ; Mazumdar M; Gulati SC; Bajorin DF; Lyn P; Vlamis V; Bosl GJ
    J Natl Cancer Inst; 1993 Nov; 85(22):1828-35. PubMed ID: 7693955
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Early salvage therapy for germ cell cancer using high dose chemotherapy with autologous bone marrow support.
    Broun ER; Nichols CR; Turns M; Williams SD; Loehrer PJ; Roth BJ; Lazarus HM; Einhorn LH
    Cancer; 1994 Mar; 73(6):1716-20. PubMed ID: 7512438
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High dose carboplatin/VP-16 plus ifosfamide with autologous bone marrow support in the treatment of refractory germ cell tumors.
    Broun ER; Nichols CR; Tricot G; Loehrer PJ; Williams SD; Einhorn LH
    Bone Marrow Transplant; 1991 Jan; 7(1):53-6. PubMed ID: 1646050
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I trial of high-dose melphalan, high-dose etoposide and autologous bone marrow re-infusion in solid tumors: an Eastern Cooperative Oncology Group (ECOG) study.
    Lazarus HM; Gray R; Ciobanu N; Winter J; Weiner RS
    Bone Marrow Transplant; 1994 Sep; 14(3):443-8. PubMed ID: 7994270
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term outcome of patients with relapsed and refractory germ cell tumors treated with high-dose chemotherapy and autologous bone marrow rescue.
    Broun ER; Nichols CR; Kneebone P; Williams SD; Loehrer PJ; Einhorn LH; Tricot GJ
    Ann Intern Med; 1992 Jul; 117(2):124-8. PubMed ID: 1318648
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase I study of high-dose ifosfamide and escalating doses of carboplatin with autologous bone marrow support.
    Elias AD; Ayash LJ; Eder JP; Wheeler C; Deary J; Weissman L; Schryber S; Hunt M; Critchlow J; Schnipper L
    J Clin Oncol; 1991 Feb; 9(2):320-7. PubMed ID: 1846407
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I and II study of high-dose ifosfamide, carboplatin, and etoposide with autologous bone marrow rescue in lymphomas and solid tumors.
    Wilson WH; Jain V; Bryant G; Cowan KH; Carter C; Cottler-Fox M; Goldspiel B; Steinberg SM; Longo DL; Wittes RE
    J Clin Oncol; 1992 Nov; 10(11):1712-22. PubMed ID: 1403054
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A multi-center prospective phase II study of high-dose chemotherapy in germ-cell cancer patients relapsing from complete remission.
    Rodenhuis S; de Wit R; de Mulder PH; Keizer HJ; Sleijfer DT; Lalisang RI; Bakker PJ; Mandjes I; Kooi M; de Vries EG
    Ann Oncol; 1999 Dec; 10(12):1467-73. PubMed ID: 10643538
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Paclitaxel-based high-dose chemotherapy with autologous stem cell rescue for relapsed germ cell cancer.
    Margolin KA; Doroshow JH; Frankel P; Chow W; Leong LA; Lim D; McNamara M; Morgan RJ; Shibata S; Somlo G; Twardowski P; Yen Y; Kogut N; Schriber J; Alvarnas J; Stalter S
    Biol Blood Marrow Transplant; 2005 Nov; 11(11):903-11. PubMed ID: 16275593
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High-dose chemotherapy and autologous bone marrow rescue for patients with refractory germ cell tumors. Early intervention is better tolerated.
    Motzer RJ; Gulati SC; Crown JP; Weisen S; Doherty M; Herr H; Fair W; Sheinfeld J; Sogani P; Russo P
    Cancer; 1992 Jan; 69(2):550-6. PubMed ID: 1309436
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High-dose etoposide, thiotepa, and dose-adjusted carboplatin (TVCa) with autologous hematopoietic stem cell rescue as treatment of relapsed or refractory germ cell cancer.
    Chaudhary UB; Damon LE; Rugo HS; Linker CA; Navarro W; Small EJ
    Am J Clin Oncol; 2005 Apr; 28(2):130-7. PubMed ID: 15803005
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Salvage therapy with high-dose chemotherapy and autologous bone marrow support in the treatment of primary nonseminomatous mediastinal germ cell tumors.
    Broun ER; Nichols CR; Einhorn LH; Tricot GJ
    Cancer; 1991 Oct; 68(7):1513-5. PubMed ID: 1654195
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.